Pfizer has developed pills for COVID-19: their effectiveness is almost 90%
Pfizer said its COVID-19 pill reduced the risk of hospitalization or death by 89% in a clinical trial. The drug was tested on adults infected with coronavirus who were in high-risk groups for severe disease. The edition told in more detail NPR.
The oral medication is called Paxloid. Like the new Merck pill that has been approved in the UKPfizer said their drug has shown good results after five days of treatment since the first symptoms of COVID-19 appeared.
Based on the credibility of the study's findings, Pfizer says it is stopping recruiting people for additional clinical trials of the pill and will instead send the findings to the FDA for emergency use.
“The data shows that our candidate for oral antiviral drugsif approved or sanctioned by regulators could save lives of patients, reduce the severity of COVID-19 infections and eliminate up to nine out of ten hospitalizations, ”said Pfizer CEO Albert Burla.
On the subject: Antibiotics for COVID-19: why it is useless and even dangerous
Both antiviral drugs from Pfizer and Merck attack the coronavirus by disrupting its ability to replicate itself.
Pfizer says their pill is enhanced by the simultaneous administration of a low dose of ritonavir, a drug used in HIV / AIDS treatment regimens. Ritonavir helps protease inhibitors like Pfizer stay in the human body longer, making them more effective against the virus.
Officials in both the US and the UK say effective COVID-19 pills could be a game-changer in the fight against the pandemic because the pills can be easily taken at home. The Regeneron antibody cocktail has become a key tool in healthcare professionals' efforts to prevent the worst outcomes for people infected with COVID-19, but monoclonal antibody treatment requires either an intravenous infusion or a series of shots.
You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - read it all on ForumDaily New York
Pfizer says its drug could be prescribed to reduce the severity of illness in COVID-19 patients, as well as to reduce the chances of infection in adults after exposure to the coronavirus.
"It has demonstrated potent antiviral activity against circulating variants of concern as well as other known coronaviruses, demonstrating its potential as a therapeutic agent for several types of coronavirus infections," the company said during a drug trial announcement.
Read also on ForumDaily:
stdClass Object ([term_id] => 12296 [name] => tablets [taxonomy] => post_tag [slug] => tabletki)pills
stdClass Object ([term_id] => 13992 [name] => Likbez [taxonomy] => category [slug] => poleznaja-informatsija)Educational program
stdClass Object ([term_id] => 28347 [name] => Special projects [taxonomy] => category [slug] => specproekty)Special Projects
stdClass Object ([term_id] => 28353 [name] => READ ABOUT CORONAVIRUS [taxonomy] => special [slug] => kitajskij-koronavirus)
stdClass Object ([term_id] => 28455 [name] => COVID-19 [taxonomy] => post_tag [slug] => covid-19)COVID-19
Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram - there are many interesting things. And join thousands of readers ForumDaily Woman и ForumDaily New York - there you will find a lot of interesting and positive information.